CN110437339B - 一种以白介素15为活性成分的融合蛋白型药物前体 - Google Patents

一种以白介素15为活性成分的融合蛋白型药物前体 Download PDF

Info

Publication number
CN110437339B
CN110437339B CN201810420739.6A CN201810420739A CN110437339B CN 110437339 B CN110437339 B CN 110437339B CN 201810420739 A CN201810420739 A CN 201810420739A CN 110437339 B CN110437339 B CN 110437339B
Authority
CN
China
Prior art keywords
ser
leu
val
thr
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810420739.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN110437339A (zh
Inventor
傅阳心
彭华
郭静雅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yiming Kangda Beijing Biopharmaceutical Co ltd
Original Assignee
Immune Targeting Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201810420739.6A priority Critical patent/CN110437339B/zh
Application filed by Immune Targeting Inc filed Critical Immune Targeting Inc
Priority to JP2020560958A priority patent/JP7684047B2/ja
Priority to AU2019262590A priority patent/AU2019262590B2/en
Priority to US17/051,160 priority patent/US12441781B2/en
Priority to CN202510533066.5A priority patent/CN120463816A/zh
Priority to CA3099039A priority patent/CA3099039A1/en
Priority to KR1020207034734A priority patent/KR20210028150A/ko
Priority to EP19796151.9A priority patent/EP3788068A4/en
Priority to CN201980045118.7A priority patent/CN112585161B/zh
Priority to CN202510533077.3A priority patent/CN120463817A/zh
Priority to PCT/US2019/030594 priority patent/WO2019213517A1/en
Publication of CN110437339A publication Critical patent/CN110437339A/zh
Application granted granted Critical
Publication of CN110437339B publication Critical patent/CN110437339B/zh
Priority to JP2025082038A priority patent/JP2025124695A/ja
Priority to US19/330,743 priority patent/US20260070957A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201810420739.6A 2018-05-04 2018-05-04 一种以白介素15为活性成分的融合蛋白型药物前体 Active CN110437339B (zh)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CN201810420739.6A CN110437339B (zh) 2018-05-04 2018-05-04 一种以白介素15为活性成分的融合蛋白型药物前体
PCT/US2019/030594 WO2019213517A1 (en) 2018-05-04 2019-05-03 Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof
US17/051,160 US12441781B2 (en) 2018-05-04 2019-05-03 Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof
CN202510533066.5A CN120463816A (zh) 2018-05-04 2019-05-03 白介素15融合蛋白及其组合物和治疗方法
CA3099039A CA3099039A1 (en) 2018-05-04 2019-05-03 Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof
KR1020207034734A KR20210028150A (ko) 2018-05-04 2019-05-03 인터루킨 15 융합 단백질, 이의 조성물 및 치료 방법
JP2020560958A JP7684047B2 (ja) 2018-05-04 2019-05-03 インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法
CN201980045118.7A CN112585161B (zh) 2018-05-04 2019-05-03 白介素15融合蛋白及其组合物和治疗方法
CN202510533077.3A CN120463817A (zh) 2018-05-04 2019-05-03 白介素15融合蛋白及其组合物和治疗方法
AU2019262590A AU2019262590B2 (en) 2018-05-04 2019-05-03 Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof
EP19796151.9A EP3788068A4 (en) 2018-05-04 2019-05-03 Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof
JP2025082038A JP2025124695A (ja) 2018-05-04 2025-05-15 インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法
US19/330,743 US20260070957A1 (en) 2018-05-04 2025-09-16 Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810420739.6A CN110437339B (zh) 2018-05-04 2018-05-04 一种以白介素15为活性成分的融合蛋白型药物前体

Publications (2)

Publication Number Publication Date
CN110437339A CN110437339A (zh) 2019-11-12
CN110437339B true CN110437339B (zh) 2021-08-13

Family

ID=68386875

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201810420739.6A Active CN110437339B (zh) 2018-05-04 2018-05-04 一种以白介素15为活性成分的融合蛋白型药物前体
CN202510533077.3A Pending CN120463817A (zh) 2018-05-04 2019-05-03 白介素15融合蛋白及其组合物和治疗方法
CN201980045118.7A Active CN112585161B (zh) 2018-05-04 2019-05-03 白介素15融合蛋白及其组合物和治疗方法
CN202510533066.5A Pending CN120463816A (zh) 2018-05-04 2019-05-03 白介素15融合蛋白及其组合物和治疗方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202510533077.3A Pending CN120463817A (zh) 2018-05-04 2019-05-03 白介素15融合蛋白及其组合物和治疗方法
CN201980045118.7A Active CN112585161B (zh) 2018-05-04 2019-05-03 白介素15融合蛋白及其组合物和治疗方法
CN202510533066.5A Pending CN120463816A (zh) 2018-05-04 2019-05-03 白介素15融合蛋白及其组合物和治疗方法

Country Status (8)

Country Link
US (1) US12441781B2 (enExample)
EP (1) EP3788068A4 (enExample)
JP (2) JP7684047B2 (enExample)
KR (1) KR20210028150A (enExample)
CN (4) CN110437339B (enExample)
AU (1) AU2019262590B2 (enExample)
CA (1) CA3099039A1 (enExample)
WO (1) WO2019213517A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN109705211B (zh) 2017-10-26 2020-08-18 苏州复融生物技术有限公司 一种IgG1 Fc单体及其应用
CN111100211B (zh) * 2019-01-30 2022-04-08 武汉九州钰民医药科技有限公司 一种Fc融合蛋白及其应用
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
WO2021113577A1 (en) * 2019-12-05 2021-06-10 Immune Targeting Inc. Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用
AU2020403148A1 (en) * 2019-12-13 2022-06-30 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
US12459984B2 (en) * 2019-12-27 2025-11-04 National University Corporation Kobe University Cancer gene therapy drug
WO2021142476A1 (en) * 2020-01-12 2021-07-15 Dragonfly Therapeutics, Inc. Single-chain polypeptides
CN113321738A (zh) * 2020-02-27 2021-08-31 启愈生物技术(上海)有限公司 肿瘤靶向、抗cd3和t细胞激活三功能融合蛋白及其应用
US20230141575A1 (en) * 2020-03-18 2023-05-11 City Of Hope Multivalent chemokine receptor binding complexes
US20230226203A1 (en) * 2020-06-18 2023-07-20 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines
CN114057889B (zh) * 2020-07-30 2023-11-10 深圳市北科生物科技有限公司 二硫键稳定的IL15-IL15Rα复合物及其应用
EP4206219A1 (en) * 2020-08-31 2023-07-05 GI Cell, Inc. Fusion protein including il15 protein, il15 receptor alpha protein, fc domain, and il2 protein, and use thereof
KR20230104866A (ko) * 2020-09-16 2023-07-11 베이진 엘티디 인터류킨 15 작제물 및 사용 방법
CN118598977A (zh) * 2020-10-18 2024-09-06 北京志道生物科技有限公司 经修饰的il-2分子及其用途
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
CN113321736B (zh) * 2020-12-30 2024-01-09 苏州复融生物技术有限公司 一种长效化白介素15融合蛋白及其制备方法和应用
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
CA3214757A1 (en) * 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
CN116375888A (zh) * 2021-05-08 2023-07-04 上海交通大学 一种融合蛋白及其制备方法和用途
CN113817072B (zh) * 2021-10-28 2024-02-20 苏州生物医药转化工程中心 一种白细胞介素15及其受体-单克隆抗体融合蛋白的纯化贮存方法
EP4435011A4 (en) * 2021-11-15 2025-07-16 Inst Biophysics Cas FUSION PROTEIN CONSTRUCTION TAKING INTERLEUKIN 15 AS ACTIVE INGREDIENT AND USE THEREOF
WO2023160721A1 (en) * 2022-02-28 2023-08-31 Wuxi Biologics (Shanghai) Co., Ltd. Heterodimeric polypeptide complexes comprising il-15 variants and uses thereof
WO2024039973A2 (en) * 2022-08-05 2024-02-22 Staidson Biopharma Inc. Masking polypeptide, activatable novel prodrugs and methods of use thereof
KR20250135294A (ko) * 2023-02-21 2025-09-12 레메젠 코, 리미티드 암을 위한 il-15 작용제
CN118909134A (zh) * 2023-05-06 2024-11-08 北京新合睿恩生物医疗科技有限公司 IL-15融合蛋白及其mRNA序列和应用
CN116554356B (zh) * 2023-05-16 2024-01-23 武汉大学 一种hyperIL-15与sCD4及Fc的融合蛋白及其应用
AU2023476910A1 (en) * 2023-12-19 2026-07-09 Immunelogic Therapeutics, Inc. Bifunctional fusion protein composed of il-15 and t cell co-stimulatory molecule antibody
WO2026006679A1 (en) * 2024-06-28 2026-01-02 The Regents Of The University Of California Retroviral vectors
WO2026037415A1 (zh) * 2024-08-16 2026-02-19 北京清辉联诺生物科技有限责任公司 一种IL15/IL15Rα复合物及其在细胞疗法领域的应用
WO2026042913A1 (ko) * 2024-08-22 2026-02-26 주식회사 박셀바이오 재조합 개 인터루킨-15를 포함하는 종양에 이환된 개의 암 치료용 조성물
US20260109746A1 (en) * 2024-10-22 2026-04-23 Gilead Sciences, Inc. Cd4-targeted il-15 molecules and methods of use
CN121949562A (zh) * 2024-10-30 2026-05-01 钱杭江医药科技(嘉兴)有限公司 一种新型蛋白复合物的二聚体化合物及其制备方法和制药用途
CN121422192A (zh) * 2025-11-20 2026-01-30 斯霈生物医药(北京)有限公司 一种序贯给药的细胞因子靶向治疗系统及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103370339A (zh) * 2010-09-21 2013-10-23 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
CN106380521A (zh) * 2015-07-02 2017-02-08 马卫红 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
CN106459219A (zh) * 2014-12-19 2017-02-22 江苏恒瑞医药股份有限公司 白细胞介素15蛋白复合物及其用途
WO2018071918A1 (en) * 2016-10-14 2018-04-19 Xencor, Inc. Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200704908B (en) * 2004-12-13 2008-10-29 Cytos Biotechnology Ag IL-15 Antigen Arrays and uses thereof
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
EP2915569A1 (en) * 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
AU2016326575A1 (en) * 2015-09-25 2018-04-12 Altor Bioscience Corporation Interleukin-15 superagonist significantly enhances graft-versus-tumor activity
CA3001131A1 (en) * 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103370339A (zh) * 2010-09-21 2013-10-23 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
CN107880136A (zh) * 2010-09-21 2018-04-06 阿尔托生物科学有限公司 多聚体il‑15可溶性融合分子与其制造与使用方法
CN106459219A (zh) * 2014-12-19 2017-02-22 江苏恒瑞医药股份有限公司 白细胞介素15蛋白复合物及其用途
CN106380521A (zh) * 2015-07-02 2017-02-08 马卫红 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
WO2018071918A1 (en) * 2016-10-14 2018-04-19 Xencor, Inc. Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments

Also Published As

Publication number Publication date
CN112585161B (zh) 2025-05-16
AU2019262590B2 (en) 2024-09-05
CA3099039A1 (en) 2019-11-07
CN110437339A (zh) 2019-11-12
EP3788068A4 (en) 2022-01-26
JP7684047B2 (ja) 2025-05-27
JP2025124695A (ja) 2025-08-26
KR20210028150A (ko) 2021-03-11
AU2019262590A1 (en) 2020-12-03
US12441781B2 (en) 2025-10-14
US20240218047A1 (en) 2024-07-04
WO2019213517A1 (en) 2019-11-07
CN120463816A (zh) 2025-08-12
CN112585161A (zh) 2021-03-30
CN120463817A (zh) 2025-08-12
JP2021522786A (ja) 2021-09-02
EP3788068A1 (en) 2021-03-10

Similar Documents

Publication Publication Date Title
CN110437339A (zh) 一种以白介素15为活性成分的融合蛋白型药物前体
Guo et al. Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent
CN110396133B (zh) 一种以白介素12为活性成分的融合蛋白型药物前体
KR101559330B1 (ko) 암 및 만성 감염 치료를 위한, 효능제 활성을 갖는 인터루킨 2로부터 유도된 폴리펩티드
CA2909576C (en) Cytokine derived treatment with reduced vascular leak syndrome
Han et al. IL-15: IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization
RU2711979C2 (ru) Белковый комплекс интерлейкина 15 и его применение
KR102322510B1 (ko) 수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인
CN114369153A (zh) 一种白介素-2突变体
ES2255067T3 (es) Receptores para la interleucina-12 humana.
CN112625137B (zh) 一种人白细胞介素10-Fc融合蛋白及其医药用途
EP4448016A2 (en) Dual cytokine fusion proteins comprising multi-subunit cytokines
CN112618698B (zh) 一种人白细胞介素10-Fc融合蛋白的注射制剂
US20250223329A1 (en) Bifunctional fusion protein composed of il-15 and antibody against t cell co-stimulatory molecule
US20020150555A1 (en) Osteoclastgenic inhibitory agent
EP4471068A1 (en) Bifunctional molecule formed by fusion of pd1 antibody and interleukin 2
EP4396212A2 (en) Interleukin-10 muteins and fusion proteins thereof
García de Galdeano et al. B16F10 murine melanoma cells express interleukin-2 and a functional interleukin-2 receptor
CN117500518A (zh) Il-2突变蛋白及包含其的药物
JPH09512165A (ja) インターロイキン１５
EP4574845A1 (en) Il-15 mutant-fc/il-15r-alpha subunit-fc heterodimer and use thereof
CN108997489B (zh) 干扰素突变体及干扰素突变体融合抗体及其制备方法、应用
WO2024193546A1 (en) Engineered il-21 variants and methods of use thereof
Devereux et al. Granulocyte-macrophage colony-stimulating factor
WO2025129454A1 (zh) Il-15与t细胞共刺激分子抗体构成的双功能融合蛋白

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210301

Address after: 4305 green Blair Avenue, Dallas, Texas, USA

Applicant after: Immune targeting Co.,Ltd.

Address before: 100101 Beijing city Chaoyang District Datun Road No. 15

Applicant before: Institute of Biophysics, Chinese Academy of Sciences

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20240708

Address after: Room A214-1-2, 2nd Floor, Building 2, No. 9 Yike Road, Life Science Park, Changping District, Beijing, 102206

Patentee after: Yiming Kangda (Beijing) Biopharmaceutical Co.,Ltd.

Country or region after: China

Address before: 4305 green Blair Avenue, Dallas, Texas, USA

Patentee before: Immune targeting Co.,Ltd.

Country or region before: U.S.A.

TR01 Transfer of patent right